SCHEMBL2579107

SCHEMBL2579107

OC(c1ccccc1OCc1ccccc1)c1ccccc1OC(F)(F)F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.55
RXRB P28702 2/20 0.55
RXRG P48443 2/20 0.55
SGMS2 Q8NHU3 9/20 0.44
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.44
LIPE Q05469 1/20 0.43
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PTPRC P08575 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPRB P23467 1/20 0.41
PTPN6 P29350 1/20 0.41
PTPN11 Q06124 1/20 0.41
ALPG P10696 1/20 0.41
PTK2B Q14289 1/20 0.41
HTR1A P08908 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2579112 0.85 RXRA (0.46) RXRARXRBRXRGSGMS2ALDH1A1
SCHEMBL28709564 0.84 KCNK3 (0.42) RXRARXRBRXRGALDH1A1L3MBTL1
SCHEMBL28769510 0.81 SGMS2 (0.56) RXRASGMS2ALDH1A1LMNALIPE
SCHEMBL27997579 0.81 RXRA (0.71) RXRARXRBRXRGSGMS2LIPE
SCHEMBL27698312 0.80 SGMS2 (0.47) RXRARXRBRXRGSGMS2ALDH1A1
SCHEMBL477534 0.80 DRD2 (0.55) SGMS2ALDH1A1LMNALIPEMAPT
SCHEMBL2579113 0.79 PPIA (0.46) RXRARXRBRXRGSGMS2ALDH1A1
SCHEMBL11603988 0.79 MAPT (0.55) SGMS2ALDH1A1LMNALIPEMAPT
SCHEMBL31041187 0.78 SLC6A9 (0.47) SGMS2ALDH1A1LMNALIPEMAPT
SCHEMBL9302615 0.77 MAPT (0.53) SGMS2ALDH1A1LMNALIPEMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048897-B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-01 US disclosed
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-12-25 US disclosed
EP-1783110-A1 NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes SLC5A1, GPR119, SLC5A2 RXRA 1228/4885RXRB 1465/4885RXRG 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.